Skip to Content

The originating document has been archived. We cannot confirm the completeness, accuracy and currency of the content.

Trimethobenzamide Hydrochloride

Pronunciation: try-meth-oh-BEN-zuh-mide HIGH-droe-KLOR-ide
Class: Anticholinergic

Trade Names

Tigan
- Capsules 300 mg
- Injection 100 mg/mL

Pharmacology

Believed to directly affect medullary chemoreceptor trigger zone to inhibit nausea.

Pharmacokinetics

Absorption

Following IM administration, T max is 30 min. After PO administration T max is 45 min. 300 mg oral capsules are equivalent to 200 mg IM. The bioavailability of the capsule formulation compared with the solution is 100%.

Elimination

Trimethobenzamide t ½ is 7 to 9 h.

Indications and Usage

Prevention and treatment of nausea and vomiting.

Contraindications

Hypersensitivity to benzocaine or other local anesthetics. Suppositories contraindicated in newborns or premature infants; parenteral use contraindicated in children.

Dosage and Administration

Adults

PO 250 mg 3 to 4 times daily. PR 200 mg 3 to 4 times daily. IM 200 mg 3 to 4 times daily.

Children 14 to 41 kg

PO 100 to 200 mg 3 to 4 times daily. PR 100 to 200 mg 3 to 4 times daily.

Children under 14 kg

PR 100 mg 3 to 4 times daily.

General Advice

  • Do not use oral route with vomiting.
  • Use Z-track technique for IM administration.

Storage/Stability

Avoid exposure to light; store at room temperature. Avoid freezing injectable.

Drug Interactions

None well documented.

Laboratory Test Interactions

None well documented.

Adverse Reactions

Cardiovascular

Hypotension (after injection).

CNS

Mood depression; disorientation; headache; drowsiness; opisthotonos; dizziness; seizures; coma; Parkinson-like symptoms.

EENT

Blurred vision.

GI

Diarrhea.

Hematologic

Blood dyscrasias.

Hepatic

Jaundice.

Miscellaneous

Local pain, burning, stinging, redness and swelling (after injection); hypersensitivity reactions; muscle cramps.

Precautions

Pregnancy

Safety not established.

Lactation

Undetermined.

Hypersensitivity

Has been reported; discontinue use of drug at first signs of sensitivity.

Patient Information

  • Instruct patient that when used for motion sickness, medication should be taken 30 min before exposure to motion.
  • Advise patient to report these symptoms to health care provider: dizziness, yellowing of skin or eyes, muscle cramps, abnormal movements.
  • Instruct patient to avoid intake of alcoholic beverages or other CNS depressants.
  • Advise patient that drug may cause drowsiness or dizziness and to use caution while driving or performing tasks requiring mental alertness.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide